banner
 
bar

program

slides

  test

syllabus
bar
 
 

Advances in Neuropsychiatric Health WebCAST

Webcast CME Disclosure

Please read this notice and click the acknowledgement
at the bottom of the page to continue.

Intended Audience:

This course is designed for primary care physicians, psychiatrists, neurologists, geriatricians, geropsychiatrists, women’s health specialists, nurse practitioners, nurses, and related healthcare providers.

Registration:

Enrollment for this WebCAST is complimentary, and clinicians are invited to participate in this CME-certified WebCAST and/or share this invitation with other colleagues, departmental staff members, and healthcare professionals.

Grantor Support:

logoSupported by an independent educational grant from Forest Laboratories Inc.

Accreditation Statement for Jointly-Sponsored Programs:

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The University of Massachusetts Medical School and CMEducation Resources, LLC. The University of Massachusetts Medical School is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

The University of Massachusetts Medical School designates this educational activity for a maximum of 3 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Policy on Faculty and Provider Disclosure:

It is the policy of the University of Massachusetts Medical School to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the University of Massachusetts Medical School are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships with those supporting the activity or others whose products or services are discussed. Faculty disclosure will be provided in the activity materials

Faculty Disclosures:

Mark H. Pollack, MD
Grant/Research Support: BMS, Cephalon, Forest, GSK, Janssen, Lilly, NARSAD, NIDA NIMH, Pfizer, Sepracor, UCB Pharma, Wyeth
Consultant: AstraZeneca, Brain Cells Inc., BMS, Cephalon, Forest, GSK, Janssen, Jazz Pharmaceuticals, Lilly, Medavante, Neurocrine, Novartis, Otsuka Pharmaceuticals, Pfizer, Predix, Roche, Sanofi, Sepracor, UCB Pharma, Wyeth|
Speaker’s Bureau: BMS, Forest, GSK, Janssen, Lilly, Pfizer, Solvay, Wyeth
Equity: Medavante

Gus Alva, MD
Grant/Research Support: Myriad, Corcept, Takeda, BMS/Otsuka, Forest, Wyeth, Novartis, Janssen, Pfizer

George T. Grossberg, MD
Grant/Research Support: Abbott, Forest, BMSQ, Janssen, Glaxo SKB, Lilly, Novartis, Pfizer, Wyeth, Eunoe
Consultant: BMSQ, Forest, Janssen, Novartis, Wyeth, Sanofi-Aventis, Glaxo SKB, Organon, Sepracor

Kevin Gray, MD
Speaker’s Bureau: Pfizer, Lilly, Forest, Novartis

Program Faculty:

Gus Alva, MD
Medical Director
ATP Clinical Research
Costa Mesa, CA

Kevin Gray, MD
Director, Geriatric Neuropsychiatry Clinic
Dallas Veteran Affairs Medical Center
Associate Professor of Psychiatry and Neurology
University of Texas Southwestern Medical Center
Dallas, TX

George T. Grossberg, MD

Samuel W. Fordyce Professor,
Department of Psychiatry
Director, Geriatric Psychiatry
St. Louis University School of Medicine
St. Louis University Hospital
St. Louis, MO

Mark H. Pollack, MD
Director, Center for Anxiety & Traumatic Stress Disorders
Massachusetts General Hospital
Associate Professor
Harvard Medical School
Boston, MA

Educational Objectives:

  • Recognize the clinical, behavioral, physiological, and psychiatric signs and symptoms of individuals suffering from mild, moderate and severe depression, MDD, and generalized anxiety disorder.
  • Recognize and manage the special challenges posed by patients with mixed neuropsychiatric disorders, including depression, AD, and GAD.
  • Evaluate and compare the efficacy and safety features of pharmacologic agents used to treat depression, GAD, and mixed neuropsychiatric disorders.
  • Implement and participate in multimodal approaches—counseling, pharmacological, support groups, and other resources—in order to provide comprehensive management of depression, AD, and generalized anxiety disorder in a wide range of patient populations, including women, men, and the elderly.
  • Asses triggers for initiation of pharmacologic agents and stage patients with AD.
  • Recognize early stage AD treatment triggers and use diverse modalities to confirm the diagnosis of AD.
  • Categorize and implement approaches to achieve optimal reduction of adverse drug-related events in patients with AD, depression, GAD, and related conditions.

Disclaimer:

Copyright © 2007 by Pharmatecture, LLC. All rights reserved.
Reproduction, distribution, or translation without express written permission is strictly prohibited.

Content on this WebCAST reflects the opinions, output, and analyses of experts, investigators, educators, and clinicians whose activities for, while independent, are commercially supported by the sponsor noted at the start of each activity.

Content on this WebCAST is not meant to be, nor substitute for national guidelines or recommendations generated by professional, academic societies, colleges, or associations.

Content on this WebCAST is intended for educational value only. Its contents, analyses, and any recommendation made herein are intended to make scientific information and opinion available to health professionals, to stimulate thought, and further investigation. This WebCAST is not designed nor is any aspect of the contents here intended to provide advice regarding medical diagnosis or treatment for any individual case. Any decisions regarding diagnosis and/or management of any individual patient or group of patients should be made on individual basis after having consulted appropriate sources, whether they be appropriate consultants and/or guidelines and recommendations issued by national organizations, professional societies, governmental health organizations, or similar bodies. This WebCAST is not intended for use by the layman.

Opinions expressed herein are not necessarily those of Pharmatecture, LLC, program supporters or accreditors, but reflect the opinions and analyses of the experts who have authored the material. Mention of products or services does not constitute endorsement. Clinical, legal, financial, and other comments are offered for general guidance only; and professional counsel should be sought for all specific situations

bar

program

slides

  test

syllabus
bar

YES, I have read the CME information statement

Copyright (c) 2007 All rights reserved


 
6

 

 

 

 

Key Program Topics Include:
5-HTT Gene Polymorphism
Acetylcholine
AD
ADMC
Affective disorders
Alprazolam
Antidementia
Antidepressants
Azapirones
Benzodiazepine
buspirone
Cerebrovascular Adverse Events
ChEIs
cholinesterase inhibitor










Citalopram
CVAE
CYP450 Isozyme
Donepezil
DSM-IV-TR
Duloxetine
Escitalopram
Fluoxetine
GAD
Galantamine
Generalized Anxiety Disorder,
Alzheimer’s Disease
Glutamate
HAM-A
Lewy bodies
MCI

MDD
GAD
memantine
Mild Cognitive Impairment
MINI – COG
Mini Mental State Exam
MMSE
MoCA
Montreal Cognitive Assessment
MRI
Neuroimaging
Neuropsychiatric Disease
Neuropsychiatric Health
Depression
NMDA-receptor antagonist
Nun Study
Olanzapine
Parkinson’s
Paroxetine
PET
Riluzole
Rivastigmine
Serotonin
Sertraline
SSRIs
STAR*D
Suicide
Tacrine
TCAs
Tricyclic antidepressants
VaD
Vascular Dementia
Venlafaxine
Venlafaxine XR